Market Research Report
Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential
Published by
GBI Research
Published
May 18, 2012 Product code
241635
Content info
Pages: 145
Price
Abstract
Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential
Summary
GBI Research, the leading business intelligence provider, has released its latest report, "Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential", which provides key data, information and analysis for the global antibacterials market (covering tuberculosis, pneumonia, urinary tract infections, atypical bronchitis, tonsillitis, sinusitis and otitis media in the US, the top five countries in Europe and Japan).
This report offers a comprehensive insight into antibacterial market based on the seven indications covered. It provides a disease overview for each indication, market forecasting, drivers and barriers, key marketed products, pipeline information and deals information for each disease in the top seven markets, as well as profiles for the main companies operating in the market.
The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts to provide a comprehensive view of the antibacterials market.
The market is large and established, but still seeing good growth despite this due to the increasing problem of nosocomial infection and the increasing incidence of some bacterial diseases in the developed world. Despite several patent expiries, including of Levaquin, one of the highest selling antibacterials, growth will continue over the forecast period. Antibacterial stewardship programs for general practitioners and hospitals, aimed at countering the development of resistance in bacteria, will not significantly slow revenues in the forecast period. While the development of new antibacterials is not currently a hugely dynamic area, targeting multi-drug resistant TB and other indications will require innovative solutions in the future.
The antibacterials market is expected to reach $12.7 billion in 2017, growing from $11.3 billion in 2010 at a CAGR of 1.7%. The market is well served currently and patent expiries are slowing the overall growth. However, despite this saturation, hospital-acquired infections are providing an impetus to development.
Scope
Overview of the global market for antibacterials.
Breakdown of the market by region.
Market analysis for each indication - including disease overviews, market forecasting, annual cost of therapy, treatment usage patterns, key marketed products and drivers and barriers.
Comprehensive pipeline analysis by indications across all phases of development.
Company profiles including SWOT analysis for major companies operating in the market.
Key deals in the antibacterials space.
Reasons to buy
Make more informed business decisions from the insightful and in-depth analysis of the antibacterials market.
Identify the opportunities and challenges that exist within the antibacterials market.
Build effective strategies to launch pipeline products.
Identify the opportunities for collaboration with the participants in the antibacterials market.
TOC
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 10
1.2 List of Figures 12
2 Antibacterials - Introduction 14
3 Antibacterials - Overview 15
3.1 Bacterial Classification 15
3.1.1 Antimicrobial Spectrum 15
3.1.2 Bacterial Resistance 16
3.2 Antibacterial Classification 16
3.2.1 Cephalosporin Antibacterials 16
3.2.2 Penicillin Antibacterials 19
3.2.3 Quinolone Antibacterials 20
3.2.4 Macrolide Antibacterials 21
3.3 Global Revenues for Antibacterials 21
3.3.1 Global Revenue and Forecast 21
3.3.2 Revenue Share by Indication 23
3.4 The US 24
3.5 Europe (The UK, France, Germany, Spain, Italy) 25
3.6 Japan 27
3.7 Drivers and Barriers for the Antibacterials Market 28
3.7.1 Drivers for the Antibacterials Market 28
3.7.2 Barriers for the Antibacterials Market 28
3.8 Opportunities 31
3.8.1 Alliances with Academic and Research Institutions are the Way Forward for Big Pharma 31
4 Tuberculosis 32
4.1 Overview 32
4.1.1 Microbiology 33
4.1.2 Diagnosis 33
4.1.3 Treatment 33
4.1.4 Prevention 34
4.2 Tuberculosis Therapeutics Market Size 35
4.2.1 Total Revenue 35
4.2.2 Average Annual Cost of Treatment (ACT) 38
4.2.3 Treatment Usage Patterns 39
4.3 Drivers and Barriers for the Tuberculosis Therapeutics Market 42
4.3.1 Drivers for the Tuberculosis Therapeutics Market 42
4.3.2 Barriers to the Tuberculosis Therapeutics Market 43
4.4 Product Profile of the Major Marketed Products in the Tuberculosis Market 43
4.4.1 Isoniazid (Isonicotinylhydrazine, INH) 43
4.4.2 Rifampin (RIF) 44
4.4.3 Pyrazinamide (PZA) 44
4.4.4 Ethambutol (EMB) 45
5 Pneumonia 46
5.1 Overview 46
5.1.1 Microbiology 46
5.1.2 Diagnosis 46
5.1.3 Treatment 47
5.1.4 Prevention 48
5.2 Pneumonia Therapeutics Market Size 49
5.2.1 Total Revenue 49
5.2.2 Annual Cost of Treatment (ACT) 52
5.2.3 Treatment Usage Patterns 53
5.3 Drivers and Barriers to the Pneumonia Therapeutics Market 55
5.3.1 Drivers for the Pneumonia Therapeutics Market 55
5.3.2 Barriers to the Pneumonia Antibacterials Market 55
5.4 Product Profile of the Major Marketed Products in the Pneumonia Antibacterials Market 57
5.4.1 Zyvox (linezolid) 57
5.4.2 Zosyn (piperacillin and tazobactum) 58
5.4.3 Levaquin (levofloxacin) 58
5.4.4 Avelox (moxifloxacin) 59
5.4.5 Omnicef (cefnidir) 59
5.4.6 Tygacil (tigecycline) 60
5.4.7 Doribax (doripenem) 61
6 Urinary Tract Infections 62
6.1 Overview 62
6.1.1 Cystitis 62
6.1.2 Urethritis 62
6.1.3 Pyelonephritis 62
6.1.4 Microbiology 62
6.1.5 Diagnosis 62
6.1.6 Urinalysis 62
6.1.7 Urine Culture 62
6.1.8 Treatment 63
6.1.9 Prevention 64
6.2 Urinary Tract Infection Therapeutics Market Size 64
6.2.1 Total Revenue 64
6.2.2 Annual Cost of Treatment (ACT) 67
6.2.3 Treatment Usage Patterns 68
6.3 Drivers and Barriers for the Urinary Tract Infection Therapeutics Market 70
6.3.1 Drivers for the UTI Therapeutics Market 70
6.3.2 Barriers for the UTI Therapeutics Market 70
6.4 Product Profile of the Major Marketed Products in the Urinary Tract Infection Market 71
6.4.1 Doribax (doripenem) 71
6.4.2 Ciprofloxacin 72
6.4.3 Levaquin (levafloxacin) 73
6.4.4 Monurol (fosfomycin tromethamine) 74
6.4.5 Macrobid (nitrofurantoin) 74
7 Atypical Bronchitis 76
7.1 Overview 76
7.1.1 Microbiology 76
7.1.2 Diagnosis 76
7.1.3 Treatment 76
7.1.4 Prevention 76
7.2 Atypical Bronchitis Therapeutics Market Size 77
7.2.1 Total Revenue 77
7.2.2 Annual Cost of Treatment (ACT) 79
7.2.3 Treatment Usage Patterns 80
7.3 Drivers and Barriers for the Atypical Bronchitis Therapeutics Market 82
7.3.1 Drivers for the Atypical Bronchitis Therapeutics Market 82
7.3.2 Barriers for the Atypical Bronchitis Therapeutics Market 82
7.4 Marketed Products 83
8 Tonsillitis 84
8.1 Overview 84
8.1.1 Microbiology 84
8.1.2 Diagnosis 84
8.1.3 Treatment 84
8.1.4 Prevention 85
8.2 Tonsillitis Therapeutics Market Size 85
8.2.1 Total Revenue 85
8.2.2 Annual Cost of Treatment (ACT) 87
8.2.3 Treatment Usage Patterns 88
8.3 Drivers and Barriers for the Tonsillitis Therapeutics Market 90
8.3.1 Drivers for the Tonsillitis Therapeutics Market 90
8.3.2 Barriers for the Tonsillitis Therapeutics Market 90
8.4 Marketed Products 91
9 Sinusitis 92
9.1 Overview 92
9.1.1 Frontal Sinusitis (located behind the forehead) 92
9.1.2 Ethmoid Sinusitis (behind the bridge of the nose) 92
9.1.3 Sphenoid Sinusitis (behind the eyes) 92
9.1.4 Maxillary Sinusitis (behind the cheeks) 92
9.1.5 Acute Sinusitis 92
9.1.6 Chronic Sinusitis 92
9.1.7 Microbiology 93
9.1.8 Diagnosis 93
9.1.9 Treatment 93
9.1.10 Prevention 93
9.2 Sinusitis Therapeutics Market Size 94
9.2.1 Total Revenue 94
9.2.2 Annual Cost of Therapy 96
9.2.3 Therapeutic Patterns 97
9.3 Drivers and Barriers for the Sinusitis Therapeutics Market 98
9.3.1 Drivers for the Sinusitis Therapeutics Market 98
9.3.2 Barriers for the Sinusitis Therapeutics Market 99
9.4 Marketed Products 99
9.4.1 Augmentin 99
9.4.2 Levaquin 100
9.4.3 Doryx 101
10 Otitis Media 102
10.1 Overview 102
10.1.1 Acute 102
10.1.2 Serous 102
10.1.3 Chronic Suppurative 102
10.2 Otitis Media Therapeutics Market Size 103
10.2.1 Total Revenue 103
10.2.2 Annual Cost of Therapy 105
10.2.3 Therapeutic Patterns 106
10.3 Drivers and Barriers for the Otitis Media Therapeutics Market 107
10.3.1 Drivers for the Otitis Media Therapeutics Market 107
10.3.2 Barriers for the Otitis Media Therapeutics Market 107
10.4 Marketed Products 108
11 Antibacterials - Pipeline Analysis 109
11.1 Introduction 109
11.2 Global Tuberculosis Market: Pipeline Analysis 110
11.2.1 Overview 110
11.2.2 Research and Development Pipeline - Phase III 110
11.2.3 Research and Development Pipeline - Phase II 111
11.2.4 Research and Development Pipeline - Phase I 112
11.2.5 Research and Development Pipeline - Preclinical 112
11.3 Global Pneumonia Therapeutics Market: Pipeline Assessment 113
11.3.1 Overview 113
11.3.2 NDA Filed 113
11.3.3 Phase III 113
11.3.4 Phase II 114
11.3.5 Phase I 115
11.3.6 Preclinical 115
11.4 Global Urinary Tract Infection Therapeutics Market: Pipeline Assessment 116
11.4.1 Overview 116
11.4.2 Phase III 116
11.4.3 Phase II 117
11.4.4 Phase I 117
11.4.5 Discovery 117
11.5 Global Atypical Bronchitis Therapeutics Market: Pipeline Assessment 118
11.6 Global Tonsillitis Therapeutics Market: Pipeline Assessment 118
11.7 Global Sinusitis Therapeutics Market: Pipeline Assessment 118
11.8 Global Otitis Media Therapeutics Market: Pipeline Assessment 119
11.8.1 Overview 119
11.8.2 Phase II 119
11.8.3 Preclinical 119
12 Antibacterials: Competitive Landscape 120
12.1 Major Players 120
12.2 Major Company Profiles 120
12.2.1 Pfizer 120
12.2.2 Sanofi 121
12.2.3 Bayer 122
12.2.4 GlaxoSmithKline 123
12.2.5 AstraZeneca 124
12.2.6 Cubist 125
12.2.7 Daiichi Sankyo 126
12.2.8 Tetraphase 127
12.2.9 Johnson and Johnson 128
13 Antibacterials - Strategic Consolidations 129
13.1 Overview - Antibacterials Market 129
13.1.1 Deals by Indication 129
13.1.2 Deals by Year 130
13.2 Tuberculosis 130
13.2.1 Mergers and Acquisitions 130
13.2.2 Licensing and Co-Developments 130
13.3 Pneumonia 133
13.3.1 Furiex Pharmaceuticals Enters into Licensing Agreement with Janssen Pharmaceutica for JNJ-Q2 (April 19, 2011) 133
13.3.2 TaiGen Biotechnology Amends its Licensing Agreement with Warner Chilcott for Nemonoxacin (October 14, 2010) 133
13.3.3 Anacor Pharmaceuticals Enters into Licensing Agreement with GlaxoSmithKline (June 29, 2010) 134
13.3.4 Paratek Pharmaceuticals Enters into Licensing Agreement with Novartis (October 8, 2009) 134
13.3.5 AstraZeneca Enters into Co-Development Agreement with Forest Laboratories (August 12, 2009) 134
13.3.6 Protea Vaccine Enters into Co-Development Agreement with GlaxoSmithKline Biologicals (June 16, 2009) 134
13.3.7 Sanofi-aventis Enters into Licensing and Collaboration Agreement with Novozymes (December 22, 2008) 135
13.3.8 Laboratorios Farmaceuticos ROVI Enters into Co-Development Agreement with Sanofi Pasteur (May 5, 2008) 135
13.3.9 Aridis Pharmaceuticals Enters into Licensing Agreement with University of Iowa Research (February 19, 2008) 135
13.3.10 Nektar Therapeutics Enters into Co-Development Agreement with Bayer HealthCare (August 6, 2007) 135
13.3.11 Oscient Pharmaceuticals Enters into License Agreement with Menarini Group for FACTIVE (January 4, 2007) 136
13.4 UTI 136
13.4.1 Teva Pharmaceutical Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey (February 21, 2008) 136
13.4.2 NanoBio Enters into Licensing Agreement with University of Michigan (April 20, 2011) 136
13.4.3 Anacor Pharmaceuticals Enters into Licensing Agreement with GlaxoSmithKline (June 29, 2010) 136
13.4.4 Depomed Amends Licensing Agreement with Madaus (April 30, 2009) 137
13.5 Atypical Bronchitis 137
13.5.1 Teva Pharmaceutical Industries Completes Acquisition of Ratiopharm (August 10, 2010) 137
13.6 Tonsillitis 137
13.6.1 Meiji Seika Enters into Licensing Agreement with Cornerstone Biopharma (November 9, 2006) 137
13.7 Sinusitis 138
13.7.1 Oscient Pharmaceuticals Enters into License Agreement with Menarini Group for FACTIVE (January 4, 2007) 138
13.8 Otitis Media 138
13.8.1 MerLion Pharmaceuticals Enters into Licensing Agreement with Alcon Pharmaceuticals for Finafloxacin (January 11, 2011) 138
13.8.2 OctoPlus Enters into Licensing Agreement with Green Cross (November 22, 2006) 138
14 Antibacterials - Appendix 139
14.1 Market Definition 139
14.2 Abbreviations 139
14.3 Sources 141
14.4 Research Methodology 141
14.4.1 Coverage 142
14.4.2 Secondary Research 142
14.4.3 Primary Research 142
14.5 Forecasting 143
14.5.1 Epidemiology-based Forecasting 143
14.5.2 Expert Panels Validation 144
14.6 Geographical Landscape 144
14.7 Pipeline Analysis 144
14.8 Competitive Landscape 144
14.9 Contact Us 144
14.10 Disclaimer 145
List of Tables
1.1 List of Tables
Table 1: Antibacterials Market, Classification, Cephalosporin Antibacterials by Generations 18
Table 2: Antibacterials, Classification, Penicillin Antibacterials 20
Table 3: Antibacterials Market, Global, Revenue, $bn, 2002-2010 21
Table 4: Antibacterials Market, Global, Revenue Forecasts, $bn, 2010-2017 22
Table 5: Antibacterials Market, The US, Revenue, $bn, 2002-2010 24
Table 6: Antibacterials Market, The US, Revenue Forecasts, $bn, 2010-2017 24
Table 7: Antibacterials Market, EU-5, Revenue, $bn, 2002-2010 25
Table 8: Antibacterials Market, EU-5, Revenue Forecasts, $bn, 2010-2017 25
Table 9: Antibacterials Market, Japan, Revenue, $m, 2002-2010 27
Table 10: Antibacterials Market, Japan, Revenue Forecasts, $m, 2010-2017 27
Table 11: Tuberculosis Therapeutics Market, Global, Revenue, $m, 2002-2010 35
Table 12: Tuberculosis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 35
Table 13: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2010 36
Table 14: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2010-2017 36
Table 15: Tuberculosis Antibacterials Market, Global, ACT, $, 2002-2010 38
Table 16: Tuberculosis Antibacterials Market, Global, ACT, $, 2010-2017 38
Table 17: Tuberculosis Therapeutics Market, Global, Prevalence Population, '000, 2002-2010 39
Table 18: Tuberculosis Therapeutics Market, Global, Prevalence Population, '000, 2010-2017 39
Table 19: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2002-2010 40
Table 20: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2010-2017 40
Table 21: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, '000, 2002-2010 41
Table 22: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, '000, 2010-2017 41
Table 23: Pneumonia Therapeutics Market, Global, Revenue, $m, 2002-2010 49
Table 24: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 49
Table 25: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2010 50
Table 26: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 51
Table 27: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 52
Table 28: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 52
Table 29: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2010 53
Table 30: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2010-2017 53
Table 31: Urinary Tract Infection Therapeutics Market, Global, Revenue, $m, 2002-2010 64
Table 32: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 64
Table 33: Urinary Tract Infection Therapeutics Market, Global, Revenue, $m, 2002-2010 65
Table 34: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 66
Table 35: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 67
Table 36: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 67
Table 37: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 68
Table 38: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 68
Table 39: Atypical Bronchitis Therapeutics Market, Global, Revenue, $m, 2002-2010 77
Table 40: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 77
Table 41: Atypical Bronchitis Therapeutics Market, Global, Revenue, $m, 2002-2010 78
Table 42: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 78
Table 43: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 79
Table 44: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 79
Table 45: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2010 80
Table 46: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2010-2017 80
Table 47: Tonsillitis Therapeutics Market, Global, Revenue, $m, 2002-2010 85
Table 48: Tonsillitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 85
Table 49: Tonsillitis Therapeutics Market, Global, Revenue, $m, 2002-2010 86
Table 50: Tonsillitis Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 86
Table 51: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 87
Table 52: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 87
Table 53: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 88
Table 54: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 88
Table 55: Sinusitis Therapeutics Market, Global, Revenue, $bn, 2002-2010 94
Table 56: Sinusitis Therapeutics Market, Global, Revenue Forecasts, $bn, 2010-2017 94
Table 57: Sinusitis Therapeutics Market, Global, Revenue by Country, $bn 2002-2010 95
Table 58: Sinusitis Therapeutics Market, Global, Revenue Forecasts by Country, $bn, 2010-2017 95
Table 59: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 96
Table 60: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 96
Table 61: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 97
Table 62: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 97
Table 63: Otitis Media Therapeutics Market, Global, Revenue, $m, 2002-2010 103
Table 64: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 103
Table 65: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2010 104
Table 66: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 104
Table 67: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2010 105
Table 68: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2010-2017 105
Table 69: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2010 106
Table 70: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2010-2017 106
Table 71: Tuberculosis Therapeutics Market, Pipeline, Phase III Molecules, 2010 110
Table 72: Tuberculosis Therapeutics Market, Pipeline, Phase II Molecules, 2010 111
Table 73: Tuberculosis Therapeutics Market, Pipeline, Phase I Molecules, 2010 112
Table 74: Tuberculosis Therapeutics Market, Pipeline, Preclinical Molecules, 2010 112
Table 75: Pneumonia Therapeutics Market, Pipeline, NDA Filed Molecules, 2010 113
Table 76: Pneumonia Therapeutics Market, Pipeline, Phase III Molecules, 2010 113
Table 77: Pneumonia Therapeutics Market, Pipeline, Phase II Molecules, 2010 114
Table 78: Pneumonia Therapeutics Market, Pipeline, Phase I Molecules, 2010 115
Table 79: Pneumonia Therapeutics Market, Pipeline, Preclinical Molecules, 2010 115
Table 80: Urinary Tract Infection Therapeutics Market, Pipeline, Phase III Molecules, 2010 116
Table 81: Urinary Tract Infection Therapeutics Market, Pipeline, Phase II Molecules, 2010 117
Table 82: Urinary Tract Infection Therapeutics Market, Pipeline, Phase I Molecules, 2010 117
Table 83: Urinary Tract Infection Therapeutics Market, Pipeline, Discovery Molecules, 2010 117
Table 84: Atypical Bronchitis Therapeutics Market, Pipeline, Phase I Molecules, 2010 118
Table 85: Sinusitis Therapeutics Market, Pipeline, Phase I Molecules, 2010 118
Table 86: Otitis Media Therapeutics Market, Pipeline, Phase II Molecules, 2010 119
Table 87: Otitis Media Therapeutics Market, Pipeline, Preclinical Molecules, 2010 119
List of Figures
1.2 List of Figures
Figure 1: Antibacterials Market, Global, Revenue Forecasts, $bn, 2002-2017 21
Figure 2: Antibacterials Market, Global, Revenue Share by Indication, %, 2010 23
Figure 3: Antibacterials Market, The US, Revenue Forecasts, $bn, 2002-2017 24
Figure 4: Antibacterials Market, EU-5, Revenue Forecasts, $bn, 2002-2017 25
Figure 5: Antibacterials Market, Japan, Revenue Forecasts, $m, 2002-2017 27
Figure 6: Tuberculosis, Recommended Initial Therapy, 2011 33
Figure 7: Tuberculosis, Treatment Flow Pattern, 2011 34
Figure 8: Tuberculosis Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 35
Figure 9: Tuberculosis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 36
Figure 10: Tuberculosis Therapeutics Market, Global, ACT, $, 2002-2017 38
Figure 11: Tuberculosis Therapeutics Market, Global, Prevalence Population, '000, 2002-2017 39
Figure 12: Tuberculosis Therapeutics Market, Global, MDR and DOTs Treated Patients, 2002-2017 40
Figure 13: Tuberculosis Therapeutics Market, Global, Prevalence Population by Country, '000, 2002-2017 41
Figure 14: Pneumonia Therapeutics Market, Drugs used in the Treatment of Pneumonia, 2011 48
Figure 15: Pneumonia Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 49
Figure 16: Pneumonia Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 50
Figure 17: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 52
Figure 18: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2017 53
Figure 19: Urinary Tract Infection Therapeutics Market, Treatment of Uncomplicated UTI, 2011 63
Figure 20: Urinary Tract Infection Therapeutics Market, Treatment of Complicated UTI, 2011 63
Figure 21: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017 64
Figure 22: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 65
Figure 23: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 67
Figure 24: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 68
Figure 25: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017 77
Figure 26: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 78
Figure 27: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 79
Figure 28: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns, Million, 2002-2017 80
Figure 29: Tonsillitis Therapeutics Market, Global, Revenue Forecast, $m, 2002-2017 85
Figure 30: Tonsillitis Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2002-2017 86
Figure 31: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 87
Figure 32: Tonsillitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 88
Figure 33: Sinusitis Therapeutics Market, Global, Revenue Forecast, $bn, 2002-2017 94
Figure 34: Sinusitis Therapeutics Market, Global, Revenue Forecasts by Country, $bn, 2010-2017 95
Figure 35: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 96
Figure 36: Sinusitis Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 97
Figure 37: Otitis Media Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 103
Figure 38: Otitis Media Therapeutics Market, Global, Revenue Forecasts by Country, $m, 2010-2017 104
Figure 39: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy, $, 2002-2017 105
Figure 40: Otitis Media Therapeutics Market, Global, Treatment Usage Pattern, Million, 2002-2017 106
Figure 41: Tuberculosis Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 110
Figure 42: Pneumonia Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 113
Figure 43: Urinary Tract Infection Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 116
Figure 44: Otitis Media Therapeutics Market, Global, R&D Pipeline by Phase, %, 2010 119
Figure 45: Antibacterial Therapeutics Market, SWOT Analysis of Pfizer, 2010 120
Figure 46: Antibacterial Therapeutics Market, Sanofi SWOT Profile, 2010 121
Figure 47: Antibacterials Market, Bayer SWOT Profile, 2010 122
Figure 48: Antibacterials Market, GSK SWOT Profile, 2010 123
Figure 49: Antibacterials Market, AstraZeneca SWOT Profile, 2010 124
Figure 50: Antibacterial, Cubist SWOT Profile, 2010 125
Figure 51: Antibacterial, Daiichi-Sankyo SWOT Profile, 2010 126
Figure 52: Antibacterial, Tetraphase SWOT Profile, 2010 127
Figure 53: Antibacterial, Johnson & Johnson SWOT Profile, 2010 128
Figure 54: Antibacterials Market, Global, Deals by Indication (%), 2011 129
Figure 55: Antibacterials Market, Global, Deals by Year (%), 2004-2011 130
Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential published by GBI Research in May 18, 2012. This report consists of Pages: 145 and the price starts from US $ 3500.
The contents of this page may be different from the latest version. Please contact us for details.
Int'l
Toll Free (US)
Europe
Asia Pacific
